Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Haleon launched a share buyback programme of up to £330m on Friday, representing the remaining portion of the £500m allocated ...

Cocoa extract supplementation among older adults had no effect overall on the occurrence of age-related macular degeneration ...

Kotak Alternate Asset Managers have announced an investment of ₹1,050 crore in Tirupati Medicare Ltd, a contract development ...

Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

Haleon said in a prospectus filed earlier this week that it could face "possible liabilities" connected with OTC Zantac, although it is in the midst of indemnity negotiations with GSK and Pfizer ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

In early corporate news, SSE names Chief Commercial Officer Martin Pibworth as its new chief executive designate, while WH Smith agrees the sale of its UK High Street business. Here is what you need ...

Pfizer sells entire Haleon stake for $3.24 billion Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer ...

The UK pharma group – now a therapeutics and vaccines pure-play since the spin-off of Haleon in July – also ... to market ahead of a rival jab from Pfizer, which is also anticipating ...